Assessing LncRNA DQ786243 and IL-17 Expression in Oral Lichen Planus: A Case Control Study

Cairo University (CU)

Status

Unknown

Conditions

Patients With Oral Lichen Planus

Treatments

Diagnostic Test: saliva samples

Study type

Observational

Funder types

Other

Identifiers

NCT04503824

14422019590827

Details and patient eligibility

About

Observational case-control study. The current study aims to assess the salivary expression of lncRNA DQ786243 and IL-17 in OLP, to better understand the pathogenesis of OLP and provide effective targets for OLP therapy.

Full description

Oral lichen planus (OLP) is a common chronic inflammatory disease associated with cell-mediated immunological dysfunction. OLP can be seen in different clinical presentations. It can be classified as papular (reticular), atrophic (erythematous) and erosive (ulcerative, bullous).1 Numerous predisposing factors have been blamed for causing OLP, including: stress, diabetes, drugs, dental materials, autoimmune diseases, infectious agents and genetic predisposition. 2 Regarding the pathogenesis of OLP, it is a T-cell mediated inflammatory disease where antigen- specific and non-specific mechanisms are hypothesized to be involved3. Antigen-specific mechanisms include antigen presentation by basal keratinocytes and antigen-specific keratinocyte killing by CD8+ cytotoxic T-cells. Non-specific mechanisms include mast cell degranulation, basement membrane disruption, chemokines and matrix metalloproteinase (MMP) activation in OLP lesions.4 Various treatment regimens have been proposed to improve the management of symptomatic OLP, but a permanent cure is not yet available. Treatment regimens are non-specific and directed at eliminating inflammation and immunosuppression.5 Corticosteroids constitute the main stay agent, other available treatment modalities include immunosuppressants, cyclosporin, tacrolimus, and retinoids.6 Long non-coding RNAs (lncRNAs) have been identified as new regulatory molecules. They modulate protein coding gene at the chromatin remodeling level, or the transcriptional and post- transcriptional control level. They play vital roles in cell differentiation, cell growth and apoptosis. lncRNA DQ786243 is drawing attention in the pathogenesis of a variety of inflammatory immune- mediated diseases such as Crohn's disease and OLP.7, 8 A recent study suggested that lncRNA DQ786243 exert its function through interleukins (ILs) including IL-17. T-helper 17 response and its hallmark IL-17 is gaining more evidence for its role and association with many diseases such as

5 Crohn's disease, ulcerative colitis, systemic lupus erythematosus and OLP. IL-17 has been found to participate in the development of autoimmune disease, inflammatory destruction and tumor microenvironments.9, 10

Research question:

What is the salivary expression of lncRNA DQ786243 and IL-17 in Oral Lichen Planus? Population (P): Oral lichen planus Control (C): Healthy individuals Outcome (O): Salivary expression level of lncRNA DQ786243 and IL-17

Objectives:

The current study aims to assess the salivary expression of lncRNA DQ786243 and IL-17 in OLP, to better understand the pathogenesis of OLP and provide effective targets for OLP therapy.

III. Methods:

Study design Observational case-control study. 8. Settings Participants will be recruited from the diagnostic centre and Oral Medicine clinic of the Faculty of Dentistry- Cairo University. The recruitment period is expected to extend from January 2020 to January 2021.

A) Participants 9. Eligibility criteria

Inclusion criteria:

Patients diagnosed with OLP.
Patient who will agree to participate in the study.
Patients who will accept to sign the informed consent.

Exclusion criteria:

Patients suffering from any systemic disease.
Patients suffering from any local inflammatory disease or infection.
Pregnant and lactating women. ▪ Smokers.

Enrollment

52 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients diagnosed with OLP.
- Patient who will agree to participate in the study.
- Patients who will accept to sign the informed consent.

Exclusion criteria

Patients suffering from any systemic disease.
- Patients suffering from any local inflammatory disease or infection.
- Pregnant and lactating women. ▪ Smokers.